Literature DB >> 19822480

Concordance of the Psoriasis Area and Severity Index (PASI) and patient-reported outcomes in psoriasis treatment.

Ines Schäfer1, Jana Hacker, Stephan Jeff Rustenbach, Marc Radtke, Nadine Franzke, Matthias Augustin.   

Abstract

A prospective observational study was conducted to analyze to what extent the Psoriasis Area and Severity Index (PASI) is correlated to patient reported outcomes (PRO). Data were collected on 93 outpatients with psoriasis prior to (t1) and after therapy (t2). A higher PASI score was associated with impaired Quality of Life (DLQI), however associations were only weak (R = 0.24 on t1 and R = 0.36 on t2). The average improvement in PASI score was correlated moderately highly with the change of DLQI (R = 0.50) as well as with the PBI (R = 0.45). The threshold values PASI-50 and PASI-75 were likewise positively associated with PRO, but they only incompletely reflect them: about half of the patients with PASI-50 did not see their expectations met (46.9%) or were not satisfied with the condition of the skin after treatment (56.3%). A quarter of these patients experienced no benefits from the therapy. Of the patients with PASI-75, 15.4% were not satisfied with the condition of their skin. In contrast, 36% of patients who did not attain PASI-50 specified a high level of treatment satisfaction. PASI and PRO are associated but based on different concepts. In addition to clinicial severity, patient-defined benefits should be implemented in the evaluation of psoriasis care.

Entities:  

Mesh:

Year:  2009        PMID: 19822480     DOI: 10.1684/ejd.2010.0815

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN: 1167-1122            Impact factor:   3.328


  18 in total

Review 1.  [Health services research in dermatology. Current status].

Authors:  N Franzke; M Augustin
Journal:  Hautarzt       Date:  2011-03       Impact factor: 0.751

2.  Objective measurement of erythema in psoriasis using digital color photography with color calibration.

Authors:  A Raina; R Hennessy; M Rains; J Allred; J M Hirshburg; D G Diven; M K Markey
Journal:  Skin Res Technol       Date:  2015-10-30       Impact factor: 2.365

3.  [Quality of life in dermatology. From measurement to practical implementation].

Authors:  K Müller; S Karrer; C Apfelbacher; C Blome; M Berneburg; M Koller
Journal:  Hautarzt       Date:  2015-04       Impact factor: 0.751

4.  The Disruptiveness of Itchiness from Psoriasis: A Qualitative Study of the Impact of a Single Symptom on Quality of Life.

Authors:  Vanina L Taliercio; Ashley M Snyder; Lisa B Webber; Adelheid U Langner; Bianca E Rich; Abram P Beshay; Dominik Ose; Joshua E Biber; Rachel Hess; Jamie L W Rhoads; Aaron M Secrest
Journal:  J Clin Aesthet Dermatol       Date:  2021-06-01

5.  Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis.

Authors:  Howa Yeung; Joy Wan; Abby S Van Voorhees; Kristina Callis Duffin; Gerald G Krueger; Robert E Kalb; Jamie D Weisman; Brian R Sperber; Bruce A Brod; Stephen M Schleicher; Bruce F Bebo; Daniel B Shin; Andrea B Troxel; Joel M Gelfand
Journal:  J Am Acad Dermatol       Date:  2012-07-28       Impact factor: 11.527

6.  An Analysis of Patient-reported Outcomes in IXORA-S: Comparing Ixekizumab and Ustekinumab over 52 Weeks in Moderate-to-severe Psoriasis.

Authors:  Lluís Puig; Mark Lomaga; Kristin Hollister; Yves Dutronc; Lovisa Berggren; Peter C M van de Kerkhof
Journal:  Acta Derm Venereol       Date:  2020-12-09       Impact factor: 3.875

Review 7.  Biological therapies in moderate and severe psoriasis: perspectives and certainties.

Authors:  M M Constantin; E Poenaru; T Constantin; C Poenaru; V L Purcarea; B R Mateescu
Journal:  J Med Life       Date:  2014

8.  Short-Term Correlation of the Psoriasis Area Severity Index, the Nail Psoriasis Area Severity Index, and the Dermatology Life Quality Index, before and after Treatment, in Patients with Skin and Nail Psoriasis.

Authors:  Christos Prevezas; Alexander C Katoulis; Evangelia Papadavid; Pantelis Panagakis; Dimitrios Rigopoulos
Journal:  Skin Appendage Disord       Date:  2019-05-21

9.  Effect of Biologic Agents on Non-PASI Outcomes in Moderate-to-Severe Plaque Psoriasis: Systematic Review and Meta-Analyses.

Authors:  Erica L Baker; Craig I Coleman; Kurt M Reinhart; Olivia J Phung; Lisa Kugelman; Wendy Chen; C Michael White; Carla M Mamolo; Joseph C Cappelleri; William L Baker
Journal:  Dermatol Ther (Heidelb)       Date:  2012-06-19

10.  The higher proportion of men with psoriasis treated with biologics may be explained by more severe disease in men.

Authors:  David Hägg; Marie Eriksson; Anders Sundström; Marcus Schmitt-Egenolf
Journal:  PLoS One       Date:  2013-05-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.